FDA Greenlights Blockbuster Diabetes Drug Jardiance for Chronic Kidney Disease

Eli Lilly and Boehringer Ingelheim have secured another FDA approval for blockbuster diabetes drug Jardiance (empagliflozin), announcing that the agency has OK’d the drug for treating adults with chronic kidney disease.
Source: Drug Industry Daily